Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1953 1
1954 1
1955 4
1956 4
1957 4
1961 1
1963 2
1967 1
1978 5
1980 2
1981 2
1982 2
1983 1
1984 3
1985 2
1986 2
1987 2
1988 1
1989 2
1990 3
1991 6
1992 3
1993 5
1994 4
1996 3
1997 1
1998 3
1999 3
2000 3
2001 1
2002 6
2003 3
2004 9
2005 1
2006 7
2007 4
2008 4
2009 5
2010 2
2011 6
2012 5
2013 6
2014 12
2015 6
2016 8
2017 4
2018 5
2019 5
2020 3
2021 5
2022 4
2023 5
2024 3
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

187 results

Results by year

Filters applied: . Clear all
Page 1
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Rosée PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rudà R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Gørløv JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG). Ferreri AJ, et al. Among authors: ambrosetti a. Lancet Haematol. 2016 May;3(5):e217-27. doi: 10.1016/S2352-3026(16)00036-3. Epub 2016 Apr 6. Lancet Haematol. 2016. PMID: 27132696 Clinical Trial.
Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience.
Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, Devizzi L, Berger F, Ponzoni M, Borisch B, Tinguely M, Cerati M, Milani M, Orvieto E, Sanchez J, Chevreau C, Dell'Oro S, Zucca E, Cavalli F. Ferreri AJ, et al. Among authors: ambrosetti a. J Clin Oncol. 2003 Jan 15;21(2):266-72. doi: 10.1200/JCO.2003.09.139. J Clin Oncol. 2003. PMID: 12525518 Free article.
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.
Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, Sønderskov Gørløv J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG). Ferreri AJM, et al. Among authors: ambrosetti a. Lancet Haematol. 2017 Nov;4(11):e510-e523. doi: 10.1016/S2352-3026(17)30174-6. Epub 2017 Oct 17. Lancet Haematol. 2017. PMID: 29054815 Clinical Trial.
Thrombocytopenias: a clinical point of view.
Veneri D, Franchini M, Randon F, Nichele I, Pizzolo G, Ambrosetti A. Veneri D, et al. Among authors: ambrosetti a. Blood Transfus. 2009 Apr;7(2):75-85. doi: 10.2450/2008.0012-08. Blood Transfus. 2009. PMID: 19503627 Free PMC article. Review. No abstract available.
[Gynecology].
Ambrosetti A, Petignat P, Martinez de Tejada B, Boulvain M. Ambrosetti A, et al. Rev Med Suisse. 2009 Jan 14;5(186):106-9. Rev Med Suisse. 2009. PMID: 19238927 French.
Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia.
Tiacci E, De Carolis L, Simonetti E, Capponi M, Ambrosetti A, Lucia E, Antolino A, Pulsoni A, Ferrari S, Zinzani PL, Ascani S, Perriello VM, Rigacci L, Gaidano G, Della Seta R, Frattarelli N, Falcucci P, Foà R, Visani G, Zaja F, Falini B. Tiacci E, et al. Among authors: ambrosetti a. N Engl J Med. 2021 May 13;384(19):1810-1823. doi: 10.1056/NEJMoa2031298. N Engl J Med. 2021. PMID: 33979489 Clinical Trial.
Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis.
Magni M, Di Nicola M, Patti C, Scimè R, Mulè A, Rambaldi A, Intermesoli T, Viero P, Tarella C, Gueli A, Bergui L, Trentin L, Barzan A, Benedetti F, Ambrosetti A, Di Raimondo F, Chiarenza A, Parvis G, Billio A, Attolico I, Olivieri A, Montanari M, Carlo-Stella C, Matteucci P, Devizzi L, Guidetti A, Viviani S, Valagussa P, Gianni AM. Magni M, et al. Among authors: ambrosetti a. Bone Marrow Transplant. 2014 Apr;49(4):485-91. doi: 10.1038/bmt.2013.214. Epub 2014 Jan 20. Bone Marrow Transplant. 2014. PMID: 24442244 Clinical Trial.
187 results